Literature DB >> 3884114

A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis.

P A Gordon, D J Carroll, W S Etches, V Jeffrey, L Marsh, B L Morrice, D Olmstead, K G Warren.   

Abstract

Twenty patients with chronically progressive multiple sclerosis (MS) were randomised in a double-blind controlled study to assess the efficacy of plasma exchange therapy. All patients were immunosuppressed with prednisone and azathioprine and underwent either plasma exchange or sham apheresis. The 10 patients in each group were similar in age, sex, duration of disease and degree of disability. Clinical and laboratory responses were assessed immediately following the course of exchange or sham therapy, and 3 to 6 months later, by individuals blinded to the type of therapy administered. Although modest improvement was suggested on clinical examination in 7 of 10 patients exchanged and 3 of the 10 sham treated group, this was transient and was not accompanied by any change in disability status scores. No differences in abnormal laboratory investigations were demonstrable between the two patient groups following therapy. We conclude that plasma exchange therapy using this protocol is unlikely to be of clinical benefit as an adjunct in the management of chronically progressive M.S.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884114     DOI: 10.1017/s0317167100046564

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  5 in total

Review 1.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 2.  Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  I Cortese; V Chaudhry; Y T So; F Cantor; D R Cornblath; A Rae-Grant
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

3.  Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases.

Authors:  Luke Bennetto; April Totham; Pat Healy; Edwin Massey; Neil Scolding
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 4.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

Review 5.  Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review.

Authors:  T Ziemssen; S Rauer; C Stadelmann; T Henze; J Koehler; I-K Penner; M Lang; D Poehlau; M Baier-Ebert; H Schieb; S Meuth
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.